Nothing Special   »   [go: up one dir, main page]

DOP2017000034A - Compuestos de imidazopiridazina - Google Patents

Compuestos de imidazopiridazina

Info

Publication number
DOP2017000034A
DOP2017000034A DO2017000034A DO2017000034A DOP2017000034A DO P2017000034 A DOP2017000034 A DO P2017000034A DO 2017000034 A DO2017000034 A DO 2017000034A DO 2017000034 A DO2017000034 A DO 2017000034A DO P2017000034 A DOP2017000034 A DO P2017000034A
Authority
DO
Dominican Republic
Prior art keywords
compounds
imidazopiridazine
directed
methods
substitutes
Prior art date
Application number
DO2017000034A
Other languages
English (en)
Inventor
Christopher John Helal
Thomas Allen Chappie
Patrick Robert Verhoest
Matthew Merrill Hayward
Nandini Chaturbhai Patel
Erik Alphie Lachapelle
Simone Sciabola
Joseph Michael Young
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54065405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2017000034(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2017000034A publication Critical patent/DOP2017000034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención está dirigida a compuestos de Fórmula I: o una sal farmacéuticamente aceptable de los mismos, en donde los sustitutos R1, R3, R6, R7 y b son como se define en la presente. La invención también está dirigida a composiciones farmacéuticas que comprenden los compuestos, procedimientos para la fabricación de medicamentos útiles para tratamientos usando los compuestos, y métodos de preparar los compuestos.
DO2017000034A 2014-08-06 2017-02-03 Compuestos de imidazopiridazina DOP2017000034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033684P 2014-08-06 2014-08-06
US201562157129P 2015-05-05 2015-05-05

Publications (1)

Publication Number Publication Date
DOP2017000034A true DOP2017000034A (es) 2017-03-15

Family

ID=54065405

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000034A DOP2017000034A (es) 2014-08-06 2017-02-03 Compuestos de imidazopiridazina

Country Status (32)

Country Link
US (4) US9598421B2 (es)
EP (1) EP3177624B1 (es)
JP (3) JP6506833B2 (es)
KR (1) KR102061952B1 (es)
CN (1) CN106795165B (es)
AP (1) AP2017009744A0 (es)
AU (2) AU2015298378B2 (es)
BR (1) BR112017001334A2 (es)
CA (1) CA2899294C (es)
CO (1) CO2017000980A2 (es)
CR (1) CR20170035A (es)
CU (1) CU20170007A7 (es)
DK (1) DK3177624T3 (es)
DO (1) DOP2017000034A (es)
EA (1) EA031201B1 (es)
EC (1) ECSP17007336A (es)
ES (1) ES2733502T3 (es)
GE (1) GEP20196950B (es)
HU (1) HUE044040T2 (es)
IL (2) IL250478B (es)
MD (1) MD20170011A2 (es)
MX (1) MX2017001565A (es)
PE (1) PE20170295A1 (es)
PH (1) PH12017500095A1 (es)
PL (1) PL3177624T3 (es)
PT (1) PT3177624T (es)
SG (1) SG11201700243YA (es)
SV (1) SV2017005381A (es)
TN (1) TN2017000031A1 (es)
TW (2) TWI577681B (es)
UY (1) UY36257A (es)
WO (1) WO2016020786A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2877493T3 (en) 2012-07-25 2018-06-14 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
PL3177624T3 (pl) 2014-08-06 2019-09-30 Pfizer Inc. Związki imidazopirydazynowe
CN108699080B (zh) 2016-02-23 2021-05-14 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
EP3678660A4 (en) 2017-09-07 2021-07-14 Board of Regents of the University of Nebraska TRPC5 INHIBITORS AND METHOD OF USING THEM
JP2021524836A (ja) * 2018-04-13 2021-09-16 ヒールクス リミテッドＨｅａｌｘ Ｌｉｍｉｔｅｄ 脆弱ｘ症候群の治療
EP3937942A4 (en) * 2019-03-15 2022-11-16 Skyhawk Therapeutics, Inc. COMPOSITIONS AND METHODS FOR CORRECTING ABERRANT SPLICING
US20220387429A1 (en) * 2019-10-21 2022-12-08 Sk Biopharmaceuticals Co., Ltd. Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability
CN112194660B (zh) * 2020-10-20 2021-12-03 常州大学 一种pde2抑制剂苯基吡唑并嘧啶类化合物及其制备方法

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
JP3816111B2 (ja) 1997-04-09 2006-08-30 インテレクト・ニューロサイエンシズ・インコーポレーテッド β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
DE60013836T2 (de) 1999-06-28 2006-01-19 Janssen Pharmaceutica N.V. Replikationsinhibitoren des respiratorischen synzytialvirus
EP1244668B1 (en) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
KR100830859B1 (ko) 2000-04-27 2008-05-21 아스텔라스세이야쿠 가부시키가이샤 이미다조피리딘 유도체 및 이를 함유하는 의약 조성물
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU2002239764B2 (en) 2000-11-03 2007-06-21 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
WO2003000697A1 (fr) 2001-06-22 2003-01-03 Takeda Chemical Industries, Ltd. Derive de furo-isoquinoline, procede de production de ce compose et utilisation de ce compose
DE60204463T2 (de) 2001-06-27 2006-05-18 Merck Frosst Canada & Co, Kirkland Substituierte 8-Arylchinoline als PDE4-Hemmer
EP1405844A4 (en) 2001-06-29 2006-09-20 Nikken Chemicals Co Ltd CYCLOALKENONDERIVAT
WO2003008396A1 (fr) 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Derive d'oxazine actif sur le plan optique
MXPA04000538A (es) 2001-07-18 2004-05-04 Merck Patent Gmbh Derivados de 4-(bencilidenamino)-3-(metilsulfanil)-4h-1,2,4-triazin-5-ona que tienen inhibicion iv-pde y accion antagonica del fnt para tratamiento de enfermedades cardiacas y alergias.
WO2003008373A1 (de) 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosinhydrazide
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2003015789A2 (en) 2001-08-15 2003-02-27 Leo Pharma A/S A pharmaceutical composition for dermal application
MXPA04001353A (es) 2001-08-15 2004-10-27 Icos Corp 2h-ftalazin-1-onas y metodos para su uso.
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
DK1429843T3 (da) 2001-09-19 2007-04-30 Altana Pharma Ag Kombination af en PDE-inhibitor og et leukotrien-receptorantagonist
CN100496607C (zh) 2001-09-19 2009-06-10 尼科梅德有限责任公司 Nsaid与pde-4抑制剂的并用药物
WO2003035650A1 (fr) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Inhibiteur d'entree
OA12708A (en) 2001-10-02 2006-06-26 Upjohn Co Azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
KR100951218B1 (ko) 2001-10-16 2010-04-05 메모리 파마슈티칼스 코포레이션 신경계 증후군의 치료를 위한 ｐｄｅ-4 억제제로서의4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
US20040259863A1 (en) 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
US6833371B2 (en) 2001-11-01 2004-12-21 Icagen, Inc. Pyrazolopyrimidines
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
AU2002363368B2 (en) 2001-11-05 2007-12-13 Merck Patent Gmbh Hydrazono-malonitriles
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
US20030092706A1 (en) 2001-11-09 2003-05-15 Johannes Barsig Combination
IS7221A (is) 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
US20050101000A1 (en) 2002-12-11 2005-05-12 Isis Pharmaceuticals Inc. Modulation of phosphodiesterase 4B expression
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
WO2004042390A2 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
DK1615647T3 (da) 2003-04-11 2010-04-06 High Point Pharmaceuticals Llc Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
BRPI0411347A (pt) * 2003-06-10 2006-07-11 Pfizer combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
MXPA05013770A (es) 2003-06-19 2006-03-08 Pfizer Prod Inc Antagonista de neuroquinina 1.
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
BRPI0414886A (pt) 2003-09-29 2006-12-12 Topigen Pharma Inc composições de oligonucleotìdeo e métodos para o tratamento de doença incluindo condições inflamatórias
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005080361A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
CA2565965A1 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AP2007003890A0 (en) 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR051294A1 (es) 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENT FOR CONTROLLING THE FUNCTION OF THE GPR34 RECEPTOR
GB0503955D0 (en) 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
EP1910369A1 (en) * 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0605462D0 (en) 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
MEP23808A (en) 2006-04-21 2010-06-10 Pfizer Prod Inc Pyridine[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
WO2008006051A2 (en) 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
EP2295439A1 (en) 2006-08-04 2011-03-16 Merz Pharma GmbH & Co. KGaA Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
US20100105729A1 (en) 2006-10-06 2010-04-29 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as anti-inflammatory agents
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
US20080102475A1 (en) 2006-10-13 2008-05-01 Zhengyan Kan Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
JP4585610B2 (ja) 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
AU2008286946B2 (en) 2007-08-10 2013-11-21 H. Lundbeck A/S Heteroaryl amide analogues
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
US8431608B2 (en) * 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
GB2461702A (en) 2008-07-08 2010-01-13 Dyson Technology Ltd Hand drying apparatus
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
JP2012503623A (ja) 2008-09-24 2012-02-09 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピラゾール化合物
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
AU2010224485B2 (en) 2009-03-20 2014-04-17 Hg&H Pharmaceuticals (Pty) Ltd Use of pharmaceutical compositions containing mesembrenone
MX2012004990A (es) * 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10.
KR20120098745A (ko) 2009-11-25 2012-09-05 메르츠 파마 게엠베하 운트 코. 카가아 치환된 피라졸로피리미딘의 결정질 형태
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
JP2013522364A (ja) 2010-03-23 2013-06-13 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換イミダゾ［１，２−ｂ］ピリダジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用の方法
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
WO2014200882A1 (en) * 2013-06-11 2014-12-18 Janssen Pharmaceutica Nv PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
PL3177624T3 (pl) 2014-08-06 2019-09-30 Pfizer Inc. Związki imidazopirydazynowe

Also Published As

Publication number Publication date
CR20170035A (es) 2017-04-28
PH12017500095A1 (en) 2017-05-22
JP2021105002A (ja) 2021-07-26
US20190322674A1 (en) 2019-10-24
PT3177624T (pt) 2019-07-11
EA201700042A1 (ru) 2017-07-31
JP2017523209A (ja) 2017-08-17
MD20170011A2 (ro) 2017-08-31
US20160039828A1 (en) 2016-02-11
SV2017005381A (es) 2017-09-13
TN2017000031A1 (en) 2018-07-04
CA2899294C (en) 2018-07-10
CO2017000980A2 (es) 2017-04-28
IL250478B (en) 2019-06-30
UY36257A (es) 2016-04-01
AU2015298378A1 (en) 2017-02-02
AU2015298378B2 (en) 2018-08-02
TW201713666A (zh) 2017-04-16
CN106795165B (zh) 2019-09-10
KR102061952B1 (ko) 2020-01-02
ECSP17007336A (es) 2018-03-31
SG11201700243YA (en) 2017-02-27
KR20170040299A (ko) 2017-04-12
TWI629276B (zh) 2018-07-11
US10669279B2 (en) 2020-06-02
US9598421B2 (en) 2017-03-21
TW201609743A (zh) 2016-03-16
PE20170295A1 (es) 2017-03-30
MX2017001565A (es) 2017-04-27
EP3177624A1 (en) 2017-06-14
JP6506833B2 (ja) 2019-04-24
US20170145022A1 (en) 2017-05-25
PL3177624T3 (pl) 2019-09-30
GEP20196950B (en) 2019-02-25
BR112017001334A2 (pt) 2017-11-14
CA2899294A1 (en) 2016-02-06
US20180346475A1 (en) 2018-12-06
CU20170007A7 (es) 2017-06-05
AU2018253590A1 (en) 2018-11-22
IL250478A0 (en) 2017-03-30
IL266108A (en) 2019-06-30
HUE044040T2 (hu) 2019-09-30
ES2733502T3 (es) 2019-11-29
TWI577681B (zh) 2017-04-11
JP2019163256A (ja) 2019-09-26
CN106795165A (zh) 2017-05-31
EA031201B1 (ru) 2018-11-30
US10077269B2 (en) 2018-09-18
DK3177624T3 (da) 2019-07-01
AP2017009744A0 (en) 2017-02-28
WO2016020786A1 (en) 2016-02-11
EP3177624B1 (en) 2019-05-01
JP7074903B2 (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
DOP2017000034A (es) Compuestos de imidazopiridazina
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
SV2017005472A (es) Compuestos de triazolopirimidina y usos de los mismos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY37900A (es) Nuevos derivados de rapamicina
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
UY36702A (es) Piridinas sustituidas y métodos de uso
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
SV2016005294A (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano(3,4-d)(1,3)tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CO2017012994A2 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
EA201590656A1 (ru) Азаиндолины
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CL2017000242A1 (es) Compuestos de imidazopiridazina